FDA approves Drug to help infants with rare disease live longer
The U.S. Food and Drug Administration approved Lembaz injection today to help patients with infantile-onset Niemann-Pick disease type C live longer.
This new therapy marks the first treatment shown to reduce death risk for people weighing at least seven kilograms. Eligible patients must have had symptoms start before reaching age six years old previously. Earlier approved options did not offer this specific life-extending benefit to those most affected by the condition.
Doctors administer Lembaz as an intrathecal injection directly into the spinal canal every two weeks. The procedure requires a trained healthcare provider to deliver the medication directly to the central nervous system.
Analysis of thirty-six patients treated with Lembaz showed longer overall survival compared to a matched external control group. The treated group experienced a 55% reduction in death risk during the clinical studies. Median survival time reached eight point five years versus four point nine years in controls.
Common side effects include hearing problems, balance issues, tiredness, sickness, stomach pain, pain in the head, high temperature, loose stools, sickness in the stomach, and coughing. Patients require comprehensive hearing evaluations before starting therapy and regularly throughout the course to monitor risks.
“For the first time, there is a treatment shown to help adults and children with this serious disease live longer”

